Cloud-based software company Salesforce (CRM) has launched Health Cloud 2.0, a new technology that is aimed at empowering businesses and governments to deliver better health and safety for employees, customers and communities.
Health Cloud 2.0 products will be made available to businesses across all sectors. The technology has been developed keeping in mind the new hybrid work model in organizations.
The company is deploying Dreampass, a new part of the Health Cloud 2.0 portfolio, at its three-day, hybrid digital and in-person Dreamforce conference this week. (See Salesforce stock chart on TipRanks)
The technology consists of a contract tracing feature that safely collects limited, necessary data from individuals and helps monitor potential outbreaks. It also includes a vaccine management feature for governments and other organizations.
“With Health Cloud 2.0, we’re continuing to enhance our capabilities around care from anywhere, digital health credentialing, contact tracing, vaccine management, and more so that employees, customers, and communities can succeed in the new normal,” said, Kevin Riley, the SVP and GM of Healthcare and Life Sciences at Salesforce.
On September 21, Jefferies analyst Brent Thill maintained a Buy rating on Salesforce with a price target of $325 (upside potential of 26%).
Consensus among analysts is a Strong Buy based on 30 Buys and 7 Holds. The average Salesforce price target of $304.94 implies upside potential of 18.2% from current levels.
Salesforce scores a “Perfect 10” from TipRanks’ Smart Score rating system, indicating that the stock is likely to outperform market expectations.
Related News:
Accenture Plans to Acquire Experity; Analysts Remain Bullish
Li Auto Lowers Q3 Delivery Outlook; Shares Dive 4.2%
Nokia, DigitalC Collaborate to Provide Internet in Cleveland
